Amicus Therapeutics, Inc. (0HF9.L)
USD 6.64
(3.91%)
USD 6.64
(3.91%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -92.07 Million USD | 65.8% |
| 2022 | -199.57 Million USD | 2.15% |
| 2021 | -202.87 Million USD | 15.68% |
| 2020 | -242.98 Million USD | 29.3% |
| 2019 | -332.26 Million USD | -3.96% |
| 2018 | -322.47 Million USD | -60.48% |
| 2017 | -428.28 Million USD | -12.67% |
| 2016 | -195.14 Million USD | -41.87% |
| 2015 | -128.7 Million USD | -84.2% |
| 2014 | -67 Million USD | -11.06% |
| 2013 | -61.38 Million USD | -18.49% |
| 2012 | -50.23 Million USD | -3.56% |
| 2011 | -46.53 Million USD | 8.36% |
| 2010 | -53.75 Million USD | -1886.81% |
| 2009 | -4.15 Million USD | 93.64% |
| 2008 | -37.64 Million USD | 4.4% |
| 2007 | -44.56 Million USD | 0.64% |
| 2006 | -44.7 Million USD | -124.83% |
| 2005 | -20.19 Million USD | -125.77% |
| 2004 | -8.8 Million USD | -36.16% |
| 2003 | -6.46 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 17.14 Million USD | 151.05% |
| 2024 Q1 | -19.52 Million USD | -74.12% |
| 2023 Q4 | -1.51 Million USD | 94.83% |
| 2023 Q1 | -39.86 Million USD | 28.92% |
| 2023 FY | - USD | 65.8% |
| 2023 Q2 | -24.34 Million USD | 38.93% |
| 2023 Q3 | -29.2 Million USD | -19.96% |
| 2022 Q4 | -56.08 Million USD | -215.28% |
| 2022 FY | - USD | 2.15% |
| 2022 Q1 | -66.46 Million USD | 3.51% |
| 2022 Q2 | -51.54 Million USD | 22.46% |
| 2022 Q3 | -17.79 Million USD | 65.48% |
| 2021 Q2 | -35.96 Million USD | 33.42% |
| 2021 Q4 | -68.88 Million USD | -84.93% |
| 2021 FY | - USD | 15.68% |
| 2021 Q1 | -54.01 Million USD | 13.31% |
| 2021 Q3 | -37.24 Million USD | -3.57% |
| 2020 Q3 | -45.69 Million USD | -7.77% |
| 2020 Q1 | -82.16 Million USD | 2.14% |
| 2020 Q2 | -42.4 Million USD | 48.4% |
| 2020 FY | - USD | 29.3% |
| 2020 Q4 | -62.3 Million USD | -36.35% |
| 2019 Q2 | -77.57 Million USD | 30.3% |
| 2019 Q4 | -83.95 Million USD | -49.58% |
| 2019 Q3 | -56.12 Million USD | 27.65% |
| 2019 Q1 | -111.3 Million USD | -67.04% |
| 2019 FY | - USD | -3.96% |
| 2018 Q2 | -48.06 Million USD | 3.13% |
| 2018 Q4 | -66.63 Million USD | 56.2% |
| 2018 FY | - USD | -60.48% |
| 2018 Q1 | -49.61 Million USD | 17.21% |
| 2018 Q3 | -152.12 Million USD | -216.53% |
| 2017 Q1 | -45.24 Million USD | 5.86% |
| 2017 FY | - USD | -12.67% |
| 2017 Q4 | -59.92 Million USD | -19.92% |
| 2017 Q3 | -49.97 Million USD | -18.85% |
| 2017 Q2 | -42.04 Million USD | 7.07% |
| 2016 Q2 | -39.48 Million USD | -1.58% |
| 2016 FY | - USD | -41.87% |
| 2016 Q4 | -48.05 Million USD | 1.1% |
| 2016 Q3 | -48.59 Million USD | -23.06% |
| 2016 Q1 | -38.87 Million USD | 1.64% |
| 2015 FY | - USD | -84.2% |
| 2015 Q4 | -39.52 Million USD | -9.53% |
| 2015 Q3 | -36.08 Million USD | -42.25% |
| 2015 Q2 | -25.36 Million USD | -13.24% |
| 2015 Q1 | -22.39 Million USD | -6.25% |
| 2014 Q2 | -14.23 Million USD | 3.06% |
| 2014 Q3 | -16.98 Million USD | -19.34% |
| 2014 Q1 | -14.67 Million USD | -9.76% |
| 2014 FY | - USD | -11.06% |
| 2014 Q4 | -21.08 Million USD | -24.13% |
| 2013 Q2 | -15.5 Million USD | 7.39% |
| 2013 Q4 | -13.37 Million USD | 8.83% |
| 2013 Q1 | -16.74 Million USD | -8.6% |
| 2013 Q3 | -14.67 Million USD | 5.41% |
| 2013 FY | - USD | -18.49% |
| 2012 Q2 | -8.78 Million USD | 14.65% |
| 2012 Q4 | -15.42 Million USD | 5.98% |
| 2012 Q3 | -16.4 Million USD | -86.62% |
| 2012 Q1 | -10.29 Million USD | 18.68% |
| 2012 FY | - USD | -3.56% |
| 2011 Q4 | -12.66 Million USD | 0.46% |
| 2011 Q3 | -12.72 Million USD | 10.73% |
| 2011 Q1 | -9.5 Million USD | 40.69% |
| 2011 Q2 | -14.25 Million USD | -49.99% |
| 2011 FY | - USD | 8.36% |
| 2010 Q4 | -16.02 Million USD | -25.93% |
| 2010 FY | - USD | -1886.81% |
| 2010 Q3 | -12.72 Million USD | -4.95% |
| 2010 Q2 | -12.12 Million USD | 5.02% |
| 2010 Q1 | -12.76 Million USD | -136.37% |
| 2009 FY | - USD | 93.64% |
| 2009 Q4 | 35.08 Million USD | 374.44% |
| 2009 Q3 | -12.78 Million USD | 2.14% |
| 2009 Q2 | -13.06 Million USD | -9.42% |
| 2009 Q1 | -11.93 Million USD | 17.21% |
| 2008 Q1 | -8.96 Million USD | 31.91% |
| 2008 FY | - USD | 4.4% |
| 2008 Q3 | -8.91 Million USD | 12.23% |
| 2008 Q2 | -10.15 Million USD | -13.29% |
| 2008 Q4 | -14.42 Million USD | -61.71% |
| 2007 Q3 | -11.49 Million USD | -16.24% |
| 2007 Q1 | -9.87 Million USD | 14.8% |
| 2007 Q4 | -13.17 Million USD | -14.61% |
| 2007 FY | - USD | 0.64% |
| 2007 Q2 | -9.88 Million USD | -0.15% |
| 2006 FY | - USD | -124.83% |
| 2006 Q2 | -11.58 Million USD | 0.0% |
| 2006 Q1 | -11.58 Million USD | -132.05% |
| 2006 Q4 | -11.58 Million USD | 0.0% |
| 2006 Q3 | -11.58 Million USD | 0.0% |
| 2005 Q1 | -4.99 Million USD | 0.0% |
| 2005 Q3 | -4.99 Million USD | 0.0% |
| 2005 Q2 | -4.99 Million USD | 0.0% |
| 2005 Q4 | -4.99 Million USD | 0.0% |
| 2005 FY | - USD | -125.77% |
| 2004 FY | - USD | -36.16% |
| 2003 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.853% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1052.607% |
| Illumina, Inc. | -608 Million USD | 84.855% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 102.828% |
| Biogen Inc. | 2.37 Billion USD | 103.874% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 79.493% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 107.91% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 79.035% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 193.708% |
| Waters Corporation | 1.02 Billion USD | 109.007% |
| Perrigo Company plc | 646.2 Million USD | 114.249% |
| uniQure N.V. | -253.1 Million USD | 63.62% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 73.346% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 65.383% |
| bluebird bio, Inc. | -167.16 Million USD | 44.916% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 21.735% |
| Imunon, Inc. | -20.78 Million USD | -343.065% |
| Myriad Genetics, Inc. | -67.8 Million USD | -35.81% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 122.129% |
| Nektar Therapeutics | -243.1 Million USD | 62.124% |
| Editas Medicine, Inc. | -163.11 Million USD | 43.55% |
| Verastem, Inc. | -83.16 Million USD | -10.717% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.184% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -107.214% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 11.285% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -146.973% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 129.676% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -5.321% |
| Evolus, Inc. | -41.81 Million USD | -120.232% |
| Adicet Bio, Inc. | -136.53 Million USD | 32.56% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -4.653% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.978% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 38.658% |
| FibroGen, Inc. | -261.4 Million USD | 64.775% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 105.491% |
| OPKO Health, Inc. | -65.51 Million USD | -40.544% |
| Homology Medicines, Inc. | -47.75 Million USD | -92.811% |
| Geron Corporation | -174.78 Million USD | 47.318% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 59.636% |
| Exelixis, Inc. | 196.6 Million USD | 146.835% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 8.676% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -65.146% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 81.814% |
| Zoetis Inc. | 3.68 Billion USD | 102.499% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 59.074% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -82.075% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.999% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -155.194% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 59.967% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 185.003% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 120.374% |
| Blueprint Medicines Corporation | -474.61 Million USD | 80.599% |
| Insmed Incorporated | -654.73 Million USD | 85.937% |
| TG Therapeutics, Inc. | 26.1 Million USD | 452.793% |
| Incyte Corporation | 919.42 Million USD | 110.015% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 81.777% |